Argus Research Maintains Buy on CVS Health, Raises Price Target to $114
Argus Research analyst Steve Silver maintains CVS Health (NYSE:CVS) with a Buy and raises the price target from $104 to $114.
Read original at benzingaStocks · News reference
CVS stock has given up its prior gain. CVS shares were trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 EPS guidance. Also, the company issued FY26 revenue guidance above estimates.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 5, 2026, 1:03 PM
- Checked
- Aug 5, 2026, 1:03 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Costco Is Getting Into Medicare — Here’s What Its New Health Insurance Plans Could Mean for Seniors
Costco plans a limited Medicare rollout with SCAN Group as insurers face rising costs and regulatory scrutiny.
Read original at benzinga8-K filing — CVS HEALTH Corp (CVS)
Filed: 2026-08-17 AccNo: 0001193125-26-354096 Size: 159 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarViking Global Bets Big On SpaceX While Ditching CoreWeave, Alphabet in Q2
Viking Global Investors' second-quarter 13F shows new stakes in SPCX, MS, QCOM, CVS and exits in CRWV and GOOGL.
Read original at benzinga